6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNPS	precautions	precaution	precaut	N	O
section	NN	section	section	section	N	O
:	:	:	:	:	N	O

Mortality	NNP	mortality	mortality	mortal	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Malignancy	NN	malignancy	malignancy	malign	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
migraine	NN	migraine	migraine	migrain	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
GlaxoSmithKline	NNP	glaxosmithkline	glaxosmithkline	glaxosmithklin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
423	CD	423	423	423	N	O
-	:	-	-	-	N	O
6597	CD	6597	6597	6597	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
plus	CC	plus	plus	plu	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
133	CD	133	133	133	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
mg	NNS	mg	mg	mg	N	O
kg	FW	kg	kg	kg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
673	CD	673	673	673	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
111	CD	111	111	111	N	O
;	:	;	;	;	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
only	RB	only	only	onli	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	NNS	mg	mg	mg	N	O
kg	FW	kg	kg	kg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
674	CD	674	674	674	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
over	IN	over	over	over	N	O
a	DT	a	a	a	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
hour	NN	hour	hour	hour	N	O
period	NN	period	period	period	N	O
on	IN	on	on	on	N	O
Days	NNP	days	day	day	N	O
0	CD	0	0	0	N	O
,	,	,	,	,	N	O
14	CD	14	14	14	N	O
,	,	,	,	,	N	O
28	CD	28	28	28	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
every	DT	every	every	everi	N	O
28	CD	28	28	28	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
2	CD	2	2	2	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Trial	NNP	trial	trial	trial	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
given	VBN	given	given	given	N	O
for	IN	for	for	for	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
given	VBN	given	given	given	N	O
for	IN	for	for	for	N	O
72	CD	72	72	72	N	O
weeks	NNS	weeks	week	week	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
apparent	JJ	apparent	apparent	appar	N	O
dose	SYM	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
summarized	VBN	summarized	summarized	summar	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
doses	NNS	doses	dos	dose	N	O
pooled	VBN	pooled	pooled	pool	N	O
,	,	,	,	,	N	O
unless	IN	unless	unless	unless	N	O
otherwise	RB	otherwise	otherwise	otherwis	N	O
indicated	VBN	indicated	indicated	indic	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
table	NN	table	table	tabl	N	O
displays	VBZ	displays	display	display	N	O
the	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NNS	kg	kg	kg	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
75	CD	75	75	75	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
94%	CD	94%	94%	94%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
52%	CD	52%	52%	52%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
93%	CD	93%	93%	93%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
reported	VBD	reported	reported	report	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
92%	CD	92%	92%	92%	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
and	CC	and	and	and	N	O
5.2%	CD	5.2%	5.2%	5.2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
groups	NNS	groups	group	group	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	JJ	commonly	commonly	commonli	N	O
-	:	-	-	-	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
nausea	RB	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
migraine	NN	migraine	migraine	migrain	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
was	VBD	was	wa	wa	N	O
6.2%	CD	6.2%	6.2%	6.2%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
7.1%	CD	7.1%	7.1%	7.1%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
infusion	JJ	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
lupus	JJ	lupus	lupus	lupu	N	B-AdverseReaction
nephritis	NN	nephritis	nephritis	nephriti	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
lists	NNS	lists	list	list	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SLE	NNP	sle	sle	sle	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
that	DT	that	that	that	N	O
observed	VBD	observed	observed	observ	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
plus	CC	plus	plus	plu	N	O
Standard	NNP	standard	standard	standard	N	O
of	IN	of	of	of	N	O
Care	NNP	care	care	care	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
Least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
More	JJR	more	more	more	N	O
Frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
Standard	NNP	standard	standard	standard	N	O
of	IN	of	of	of	N	O
Care	NNP	care	care	care	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
Controlled	JJ	controlled	controlled	control	N	O
SLE	NNP	sle	sle	sle	Y	O
Studies	NNS	studies	study	studi	N	O

Preferred	JJ	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	FW	kg	kg	kg	N	O
Standard	NNP	standard	standard	standard	N	O
of	IN	of	of	of	N	O
Care	NNP	care	care	care	N	O
(	(	(	(	(	N	O
n	RB	n	n	n	N	O
674	CD	674	674	674	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Standard	NNP	standard	standard	standard	N	O
of	IN	of	of	of	N	O
Care	NNP	care	care	care	N	O
(	(	(	(	(	N	O
n	RB	n	n	n	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
15	CD	15	15	15	N	O
12	CD	12	12	12	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
12	CD	12	12	12	N	O
9	CD	9	9	9	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
8	CD	8	8	8	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
9	CD	9	9	9	N	O
7	CD	7	7	7	N	O

Bronchitis	NNP	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
9	CD	9	9	9	N	O
5	CD	5	5	5	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
7	CD	7	7	7	N	O
5	CD	5	5	5	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
6	CD	6	6	6	N	O
4	CD	4	4	4	N	O

Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O

Migraine	NNP	migraine	migraine	migrain	Y	B-AdverseReaction
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O

Pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Gastroenteritis	NNP	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
viral	JJ	viral	viral	viral	N	I-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

6.2	CD	6.2	6.2	6.2	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

In	IN	in	in	in	N	O
Trials	NNP	trials	trial	trial	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
belimumab	NN	belimumab	belimumab	belimumab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
of	IN	of	of	of	N	O
563	CD	563	563	563	N	O
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
27	CD	27	27	27	N	O
of	IN	of	of	of	N	O
559	CD	559	559	559	N	O
(	(	(	(	(	N	O
4.8%	CD	4.8%	4.8%	4.8%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
reported	JJ	reported	reported	report	N	O
frequency	NN	frequency	frequency	frequenc	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
receiving	VBG	receiving	receiving	receiv	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
may	MD	may	may	may	N	O
underestimate	VB	underestimate	underestimate	underestim	N	O
the	DT	the	the	the	N	O
actual	JJ	actual	actual	actual	N	O
frequency	NN	frequency	frequency	frequenc	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
lower	VB	lower	lower	lower	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
drug	NN	drug	drug	drug	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
belimumab	NN	belimumab	belimumab	belimumab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
experienced	VBD	experienced	experienced	experienc	N	O
mild	JJ	mild	mild	mild	N	B-Severity
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
of	IN	of	of	of	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythematous	JJ	erythematous	erythematous	erythemat	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
;	:	;	;	;	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
belimumab	NN	belimumab	belimumab	belimumab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
test	NN	test	test	test	N	O
results	NNS	results	result	result	N	O
were	VBD	were	were	were	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
belimumab	VB	belimumab	belimumab	belimumab	N	O
in	IN	in	in	in	N	O
specific	JJ	specific	specific	specif	N	O
assays	NNS	assays	assay	assay	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
,	,	,	,	,	N	O
assay	VBP	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
belimumab	VB	belimumab	belimumab	belimumab	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
postapproval	JJ	postapproval	postapproval	postapprov	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Mortality	NN	mortality	mortality	mortal	N	B-AdverseReaction
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
interrupting	VBG	interrupting	interrupting	interrupt	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
if	IN	if	if	if	N	O
patients	NNS	patients	patient	patient	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
Multifocal	NNP	multifocal	multifocal	multifoc	N	I-AdverseReaction
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
presenting	VBG	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
new	JJ	new	new	new	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
or	CC	or	or	or	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
PML	NNP	pml	pml	pml	N	O
by	IN	by	by	by	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
specialist	NN	specialist	specialist	specialist	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
PML	NNP	pml	pml	pml	N	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
by	IN	by	by	by	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
prepared	VBD	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Depression	NN	depression	depression	depress	Y	B-AdverseReaction
:	:	:	:	:	N	O
Depression	NN	depression	depression	depress	Y	B-AdverseReaction
and	CC	and	and	and	N	O
suicidality	NN	suicidality	suicidality	suicid	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
experience	VBP	experience	experience	experi	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
mood	NN	mood	mood	mood	N	O
changes	NNS	changes	change	chang	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Immunization	NN	immunization	immunization	immun	Y	O
:	:	:	:	:	N	O
Live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Mortality	NN	mortality	mortality	mortal	N	O

There	EX	there	there	there	N	O

were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
133	CD	133	133	133	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
14	CD	14	14	14	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
treatment	NN	treatment	treatment	treatment	N	O
periods	NNS	periods	period	period	N	O
:	:	:	:	:	N	O
3	CD	3	3	3	N	O
675	CD	675	675	675	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
673	CD	673	673	673	N	O
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
111	CD	111	111	111	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
674	CD	674	674	674	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
groups	NNS	groups	group	group	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
4	CD	4	4	4	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
single	JJ	single	single	singl	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
predominated	VBN	predominated	predominated	predomin	N	O
.	.	.	.	.	N	O

Etiologies	NNS	etiologies	etiology	etiolog	N	O
included	VBD	included	included	includ	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
,	,	,	,	,	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Serious	JJ	serious	serious	seriou	N	O
Infections	NNS	infections	infection	infect	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
exercise	VB	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
considering	VBG	considering	considering	consid	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
any	DT	any	any	ani	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
chronic	JJ	chronic	chronic	chronic	N	O
infection	NN	infection	infection	infect	Y	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
begin	VB	begin	begin	begin	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
interrupting	VBG	interrupting	interrupting	interrupt	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
infection	NN	infection	infection	infect	Y	O
while	IN	while	while	while	N	O
undergoing	VBG	undergoing	undergoing	undergo	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
71%	CD	71%	71%	71%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
67%	CD	67%	67%	67%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
5.2%	CD	5.2%	5.2%	5.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
included	VBD	included	included	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
death	NN	death	death	death	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
458	CD	458	458	458	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Progressive	JJ	progressive	progressive	progress	N	O
Multifocal	NNP	multifocal	multifocal	multifoc	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	O
)	)	)	)	)	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
deficits	NNS	deficits	deficit	deficit	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SLE	NNP	sle	sle	sle	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
PML	NNP	pml	pml	pml	N	O
include	VBP	include	include	includ	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	O
therapies	NNS	therapies	therapy	therapi	N	O
and	CC	and	and	and	N	O
impairment	NN	impairment	impairment	impair	N	O
of	IN	of	of	of	N	O
immune	JJ	immune	immune	immun	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
patient	JJ	patient	patient	patient	N	O
presenting	NN	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
new	JJ	new	new	new	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
or	CC	or	or	or	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
consult	NN	consult	consult	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
neurologist	NN	neurologist	neurologist	neurologist	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
specialist	NN	specialist	specialist	specialist	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
PML	NNP	pml	pml	pml	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
stopping	VBG	stopping	stopping	stop	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Malignancy	NN	malignancy	malignancy	malign	N	O

The	DT	the	the	the	N	O
impact	NN	impact	impact	impact	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	B-Factor
known	VBN	known	known	known	N	I-Factor
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
non	SYM	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
cancers	NNS	cancers	cancer	cancer	N	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
skin	NN	skin	skin	skin	N	O
cancers	NNS	cancers	cancer	cancer	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
458	CD	458	458	458	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
could	MD	could	could	could	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
generally	RB	generally	generally	gener	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
hours	NNS	hours	hour	hour	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
they	PRP	they	they	they	N	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
later	RB	later	later	later	N	O
.	.	.	.	.	N	O

Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
acute	NN	acute	acute	acut	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
and	CC	and	and	and	N	O
typically	RB	typically	typically	typic	N	O
occurred	VBD	occurred	occurred	occur	N	O
up	RP	up	up	up	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
week	NN	week	week	week	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
recent	JJ	recent	recent	recent	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
previously	RB	previously	previously	previous	N	O
tolerated	VBN	tolerated	tolerated	toler	N	O
infusions	NNS	infusions	infusion	infus	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Limited	VBN	limited	limited	limit	N	O
data	NNS	data	data	data	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
multiple	JJ	multiple	multiple	multipl	N	O
drug	NN	drug	drug	drug	N	O
allergies	NNS	allergies	allergy	allergi	N	O
or	CC	or	or	or	N	O
significant	JJ	significant	significant	signific	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
(	(	(	(	(	N	O
191	CD	191	191	191	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
458	CD	458	458	458	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
11%	CD	11%	11%	11%	N	O
(	(	(	(	(	N	O
76	CD	76	76	76	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
458	CD	458	458	458	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Manifestations	NNS	manifestations	manifestation	manifest	N	O
included	VBD	included	included	includ	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
overlap	VB	overlap	overlap	overlap	N	O
in	IN	in	in	in	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
distinguish	VB	distinguish	distinguish	distinguish	N	O
between	IN	between	between	between	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
cases	NNS	cases	case	case	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
received	VBN	received	received	receiv	N	O
premedication	NN	premedication	premedication	premed	Y	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
mitigated	VBN	mitigated	mitigated	mitig	N	O
or	CC	or	or	or	N	O
masked	VBN	masked	masked	mask	N	O
a	DT	a	a	a	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
response	NN	response	response	respons	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
evidence	NN	evidence	evidence	evid	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
premedication	NN	premedication	premedication	premed	Y	O
diminishes	VBZ	diminishes	diminishes	diminish	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
by	IN	by	by	by	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
prepared	VBD	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
therapy	NN	therapy	therapy	therapi	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
informed	VBN	informed	informed	inform	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
acute	JJ	acute	acute	acut	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
and	CC	and	and	and	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
a	DT	a	a	a	N	O
reaction	NN	reaction	reaction	reaction	N	O
occur	NN	occur	occur	occur	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Infusion	NNP	infusion	infusion	infus	Y	O
Reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
associated	VBN	associated	associated	associ	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
infusion	NN	infusion	infusion	infus	Y	I-AdverseReaction
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
17%	CD	17%	17%	17%	N	O
(	(	(	(	(	N	O
251	CD	251	251	251	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
458	CD	458	458	458	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
15%	CD	15%	15%	15%	N	O
(	(	(	(	(	N	O
99	CD	99	99	99	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
overlap	VB	overlap	overlap	overlap	N	O
in	IN	in	in	in	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
distinguish	VB	distinguish	distinguish	distinguish	N	O
between	IN	between	between	between	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
cases	NNS	cases	case	case	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
received	VBN	received	received	receiv	N	O
premedication	NN	premedication	premedication	premed	Y	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
mitigated	VBN	mitigated	mitigated	mitig	N	O
or	CC	or	or	or	N	O
masked	VBN	masked	masked	mask	N	O
an	DT	an	an	an	N	O
infusion	NN	infusion	infusion	infus	Y	O
reaction	NN	reaction	reaction	reaction	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
evidence	NN	evidence	evidence	evid	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
premedication	NN	premedication	premedication	premed	Y	O
diminishes	VBZ	diminishes	diminishes	diminish	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
by	IN	by	by	by	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
prepared	VBD	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
rate	NN	rate	rate	rate	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
slowed	VBN	slowed	slowed	slow	N	O
or	CC	or	or	or	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
an	DT	an	an	an	N	O
infusion	NN	infusion	infusion	infus	Y	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

Healthcare	NNP	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
aware	JJ	aware	aware	awar	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
present	VB	present	present	present	N	O
as	IN	as	a	as	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Depression	NN	depression	depression	depress	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
related	VBN	related	related	relat	N	O
primarily	RB	primarily	primarily	primarili	N	O
to	TO	to	to	to	N	O
depression	VB	depression	depression	depress	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
6.3%	CD	6.3%	6.3%	6.3%	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
5.3%	CD	5.3%	5.3%	5.3%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
(	(	(	(	(	N	O
3.9%	CD	3.9%	3.9%	3.9%	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
and	CC	and	and	and	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
depression	NN	depression	depression	depress	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
458	CD	458	458	458	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
and	CC	and	and	and	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
675	CD	675	675	675	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
suicides	NNS	suicides	suicide	suicid	N	B-AdverseReaction
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
depression	NN	depression	depression	depress	Y	B-AdverseReaction
or	CC	or	or	or	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
most	JJS	most	most	most	N	O
were	VBD	were	were	were	N	O
receiving	VBG	receiving	receiving	receiv	N	O
psychoactive	JJ	psychoactive	psychoactive	psychoact	N	O
medications	NNS	medications	medication	medic	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
if	IN	if	if	if	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
experience	VBP	experience	experience	experi	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
mood	NN	mood	mood	mood	N	O
changes	NNS	changes	change	chang	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Immunization	NN	immunization	immunization	immun	Y	O

Live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
for	IN	for	for	for	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
before	IN	before	before	befor	N	O
or	CC	or	or	or	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
as	IN	as	a	as	N	O
clinical	JJ	clinical	clinical	clinic	N	O
safety	NN	safety	safety	safeti	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
data	NN	data	data	data	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
secondary	JJ	secondary	secondary	secondari	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
from	IN	from	from	from	N	O
persons	NNS	persons	person	person	N	O
receiving	VBG	receiving	receiving	receiv	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
on	IN	on	on	on	N	O
new	JJ	new	new	new	N	O
immunizations	NNS	immunizations	immunization	immun	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
may	MD	may	may	may	N	O
interfere	VB	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
immunizations	NNS	immunizations	immunization	immun	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Other	JJ	other	other	other	N	O
Biologic	NNP	biologic	biologic	biolog	N	O
Therapies	NNPS	therapies	therapy	therapi	N	O
or	CC	or	or	or	N	O
Intravenous	NNP	intravenous	intravenous	intraven	N	O
Cyclophosphamide	NNP	cyclophosphamide	cyclophosphamide	cyclophosphamid	N	O

BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
biologic	JJ	biologic	biologic	biolog	N	O
therapies	NNS	therapies	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
B	NNP	b	b	b	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
targeted	JJ	targeted	targeted	target	N	O
therapies	NNS	therapies	therapy	therapi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
cyclophosphamide	NN	cyclophosphamide	cyclophosphamide	cyclophosphamid	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
BENLYSTA	NNP	benlysta	benlysta	benlysta	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
biologic	JJ	biologic	biologic	biolog	N	O
therapies	NNS	therapies	therapy	therapi	N	O
or	CC	or	or	or	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
cyclophosphamide	NN	cyclophosphamide	cyclophosphamide	cyclophosphamid	N	O
.	.	.	.	.	N	O

